Osteoglycin (OGN)

Osteoglycin is a small leucine-rich proteoglycan (SLRP), also known as OGN or mimecan, and was initially isolated as an "osteoinductive factor" from bone[1]. It is characterized by seven leucine-rich repeats and belongs to SLRP class III, with a molecular core protein of approximately 32 kDa[1]. Osteoglycin is secreted by muscle cells, osteoblasts, and fibroblasts, and plays critical roles in bone-anabolic processes by modulating late-stage osteoblast differentiation and enhancing the expression of matrix proteins such as type I collagen, osteocalcin, and alkaline phosphatase. OGN also interacts with the TGF-β signaling pathway to regulate collagen gene expression and bone matrix mineralization independently of TGF-β concentration, possibly through Smad3/4[1]. In addition to its role in bone and extracellular matrix formation, osteoglycin has functions in broader physiological systems, including modulation of glucose and energy homeostasis. Studies in mouse models show that osteoglycin acts as a negative regulator of osteoblast activity, helps coordinate bone formation with metabolic state, and influences insulin secretion and glucose tolerance—potentially linking skeletal and metabolic health[2]. Osteoglycin is associated with disease processes such as arteriogenesis, musculoskeletal disorders, and possibly certain cancers, where it seems to inhibit metastatic behaviors in cell models[1][2]. Biomarker studies have also linked circulating osteoglycin levels to changes in BMI, lean body mass, and weight in humans undergoing interventions such as bariatric surgery[2]. There are currently no known therapeutic drugs that directly target osteoglycin, and it is not considered a classical drug target such as a receptor, enzyme, or transporter.

Other names

MimecanOsteoinductive factorSmall leucine-rich proteoglycan class III member 7